Joanne Ngeow1, Kim Stanuch1, Jessica L Mester1, Jill S Barnholtz-Sloan1, Charis Eng2. 1. Joanne Ngeow, Kim Stanuch, Jessica L. Mester, and Charis Eng, Cleveland Clinic; and Jill S. Barnholtz-Sloan and Charis Eng, Case Western Reserve University, Cleveland, OH. 2. Joanne Ngeow, Kim Stanuch, Jessica L. Mester, and Charis Eng, Cleveland Clinic; and Jill S. Barnholtz-Sloan and Charis Eng, Case Western Reserve University, Cleveland, OH. engc@ccf.org.
Abstract
PURPOSE: Patients with Cowden syndrome (CS) with underlying germline PTEN mutations are at increased risk of breast, thyroid, endometrial, and renal cancers. To our knowledge, risk of subsequent cancers in these patients has not been previously explored or quantified. PATIENTS AND METHODS: We conducted a 7-year multicenter prospective study (2005 to 2012) of patients with CS or CS-like disease, all of whom underwent comprehensive PTEN mutational analysis. Second malignant neoplasms (SMNs) were ascertained by medical records and confirmed by pathology reports. Standardized incidence ratios (SIRs) for all SMNs combined and for breast, thyroid, endometrial, and renal cancers were calculated. RESULTS: Of the 2,912 adult patients included in our analysis, 2,024 had an invasive cancer history. Germline pathogenic PTEN mutations (PTEN mutation positive) were identified in 114 patients (5.6%). Of these 114 patients, 46 (40%) had an SMN. Median age of SMN diagnosis was 50 years (range, 21 to 71 years). Median interval between primary cancer and SMN was 5 years (range, <1 to 35 years). Of the 51 PTEN mutation-positive patients who presented with primary breast cancer, 11 (22%) had a subsequent new primary breast cancer and 10-year second breast cancer cumulative risk of 29% (95% CI, 15.3 to 43.7). Risk of SMNs compared with that of the general population was significantly elevated for all cancers (SIR, 7.74; 95% CI, 5.84 to 10.07), specifically for breast (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 95% CI, 3.01 to 10.18), and endometrial SMNs (SIR, 14.08.07; 95% CI, 7.10 to 27.21). CONCLUSION: Patients with CS with germline PTEN mutations are at higher risk for SMNs compared with the general population. Prophylactic mastectomy should be considered on an individual basis given the significant risk of subsequent breast cancer.
PURPOSE:Patients with Cowden syndrome (CS) with underlying germline PTEN mutations are at increased risk of breast, thyroid, endometrial, and renal cancers. To our knowledge, risk of subsequent cancers in these patients has not been previously explored or quantified. PATIENTS AND METHODS: We conducted a 7-year multicenter prospective study (2005 to 2012) of patients with CS or CS-like disease, all of whom underwent comprehensive PTEN mutational analysis. Second malignant neoplasms (SMNs) were ascertained by medical records and confirmed by pathology reports. Standardized incidence ratios (SIRs) for all SMNs combined and for breast, thyroid, endometrial, and renal cancers were calculated. RESULTS: Of the 2,912 adult patients included in our analysis, 2,024 had an invasive cancer history. Germline pathogenic PTEN mutations (PTEN mutation positive) were identified in 114 patients (5.6%). Of these 114 patients, 46 (40%) had an SMN. Median age of SMN diagnosis was 50 years (range, 21 to 71 years). Median interval between primary cancer and SMN was 5 years (range, <1 to 35 years). Of the 51 PTEN mutation-positive patients who presented with primary breast cancer, 11 (22%) had a subsequent new primary breast cancer and 10-year second breast cancer cumulative risk of 29% (95% CI, 15.3 to 43.7). Risk of SMNs compared with that of the general population was significantly elevated for all cancers (SIR, 7.74; 95% CI, 5.84 to 10.07), specifically for breast (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 95% CI, 3.01 to 10.18), and endometrial SMNs (SIR, 14.08.07; 95% CI, 7.10 to 27.21). CONCLUSION:Patients with CS with germline PTEN mutations are at higher risk for SMNs compared with the general population. Prophylactic mastectomy should be considered on an individual basis given the significant risk of subsequent breast cancer.
Authors: Paul D P Pharoah; Antonis Antoniou; Martin Bobrow; Ron L Zimmern; Douglas F Easton; Bruce A J Ponder Journal: Nat Genet Date: 2002-03-04 Impact factor: 38.330
Authors: Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals Journal: Nucleic Acids Res Date: 2002-06-15 Impact factor: 16.971
Authors: Nienke van der Stoep; Chantal D M van Paridon; Tom Janssens; Petra Krenkova; Alexandra Stambergova; Milan Macek; Gert Matthijs; Egbert Bakker Journal: Hum Mutat Date: 2009-06 Impact factor: 4.878
Authors: Kelly A Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo A Olivotto; William D Foulkes; Ellen Warner; Olufunmilayo Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; Steven A Narod Journal: Gynecol Oncol Date: 2005-01 Impact factor: 5.482
Authors: Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng Journal: Am J Hum Genet Date: 2007-08-15 Impact factor: 11.025
Authors: Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254